



Tiered Biologics Reimbursement Policy Flowsheet

New Patients (Biologic-Naïve):



Existing Patients:



*NOTE: Patients will not be permitted to switch from Abrilada, Amgevita, Avsola, Brenzys, Erelzi, Hadlima, Hulio, Hyrimoz, Idacio, Inflectra, *Jamteki, Renflexis, Riabni, Riximyo, Ruxience, *Rymti, Truxima, Simlandi, *Wezlana, *Wezlana IV, or Yuflyma to another adalimumab, etanercept, infliximab, rituximab, or ustekinumab product listed in Tier 1 and/or Tier 2 if previously trialed and deemed unresponsive to therapy.*

*NOTE: Patients will not be permitted to switch from Remicade, Enbrel, Humira, Rituxan or *Stelara to another infliximab, etanercept, adalimumab, rituximab, or *ustekinumab product listed in Tier 1 if previously trialed and deemed unresponsive to therapy.*